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Synaptic plasticityNeuronatin (NNAT) is a ubiquitous and highly conserved mammalian gene involved in brain development. Its
mRNA isoforms, chromosomal location, genomic DNA structure and regulation have been characterized. More
recently there has been rapid progress in the understanding of its function in physiology and human disease.
In particular there is fairly direct evidence implicating neuronatin in the causation of Lafora disease and diabetes.
Neuronatin protein has a strong predisposition to misfold and form cellular aggregates that cause cell death by
apoptosis. Aggregation ofNeuronatinwithin cortical neurons and resulting cell death is the hallmark of Lafora dis-
ease, a progressive and fatal neurodegenerative disease. Under high glucose conditions simulating diabetes,
neuronatin protein also accumulates and destroys pancreatic beta cells.
The neuronatin gene is imprinted and only the paternal allele is normally expressed in the adult. However, chang-
es in DNAmethylation may cause the maternal allele to lose imprinting and trigger cell proliferation andmetas-
tasis. Neuronatin has also been shown to be translated peripherally within the dendrites of neurons, a ﬁnding of
relevance in synaptic plasticity. The current understanding of the function of neuronatin raises the possibility that
this gene may participate in the common downstream mechanisms associated with aberrant neuronal growth
and death. A better understanding of these mechanisms may open new therapeutic targets to help modify the
progression of devastating neurodegenerative conditions such as Alzheimer's and anterior horn cell disease.
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Mammalian brain development, its progression tomaturity and pre-
dictable culmination in senescence is governed by differential gene ex-
pression. Therefore, the genes expressed in neonatal and adult rat brain
184 R.M. Joseph / Genomics 103 (2014) 183–188were studied in order to isolate those genes that are differentially
expressed in the developing brain. A cDNA fragment selectively
expressed in neonatal rat brain was identiﬁed by differential display
and used to screen a rat cDNA library. The full length cDNA was
observed to be a novel 1195 bp sequence that was named neuronatin
(NEUROnal-neoNATal-IN) [1,2].2. Neuronatin genomic DNA: located on human
chromosome-20q11.2-12
The rat neuronatin cDNA sequence was used to screen a human
cDNA library leading to the identiﬁcation of the human cDNA [3]. Subse-
quently, a human genomic library was screened and the human
neuronatin genomic DNA was also identiﬁed and sequenced. The gene
is located at chromosome-20q11.2-12 [4]. The mouse equivalent of
neuronatin is located in the distal portion of chomosome-2 [5]. These
chromosomal locations of neuronatin function as imprint control re-
gions residing outside of more established imprinted clusters [6]. Inter-
estingly, Neuronatin gene is located within the ﬁrst intron of a larger
gene, BLCAP (Bladder Cancer Associated Protein) which is a tumor sup-
pressor and stimulator of apoptosis [7,8].
The humangene spans 3973 bases and contains three exons and two
introns (Fig. 1). Analysis of the genomic structure and the mRNA se-
quence indicates that neuronatin gene is expressed as two mRNA spe-
cies, alpha and beta, generated by alternative splicing (Fig. 2). The
alpha-form contains all three exons, whereas, in the beta-form, themid-
dle exon has been spliced out. The ﬁrst exon contains the prototypical
translation initiation site in good context, GGAACCATG, and encodes
24 amino acid residues. Exon-2 encodes 27 amino acid residues, and
exon-3 encodes 30 amino acids. Based on the genomic structure the
alpha-form of neuronatin mRNA encodes a protein of 81 amino acids
using all three exons. The beta-form of neuronatinmRNA encodes a pro-
tein of 54 amino acids using the ﬁrst and third exons [9].
These results strongly indicate that the alpha and beta isoforms of
human neuronatin mRNA are generated by differential splicing of the
middle exon (exon-2). Interestingly, the N-terminal hydrophobic do-
main (transmembrane α-helix) is entirely encoded by exon-1, and the
C-terminal hydrophilic domain is encoded by exon-3. The signiﬁcance
of the middle exon which is neither hydrophilic nor hydrophobic in
the functioning of this gene is less clear. A more complete elucidation
of the signiﬁcance this 81basemiddle exonmay be crucial to a complete
understanding of the function of neuronatin.Fig. 1. Structure of human neuronatin gene. The neuronatin DNA sequence spans 3973 bases an
CAAT (−59) sites located upstream from the transcription start site. A single transcription sta
bases downstream from themodiﬁed TATA box. A 21 base neural restrictive silencer element (N
including imprint control sites have also been identiﬁed within the ﬁrst intron of the neurona
London 1996, page-180).3. Neuronatin gene promoter
The neuronatin promoter contains modiﬁed TATA (−27) and CAAT
(−59) sites located upstream from the transcription start site. A single
transcription start site is located 124 bases upstream from the methio-
nine (ATG) initiation codon and 27 bases downstream from the
modiﬁed TATA box. Several putative transcription factor binding sites
are found in the 5′-ﬂanking region including consensus sequences for
SP-1, AP-2 (two sites), δsubunit, SRE-2, NF-A1, ETS and NRSE. A 21 base
sequence highly homologous to the neural restrictive silence element
(NRSE) which governs neuron-speciﬁc gene expression is observed at
−421 bases. NRSE has a consensus motif, [TT(C/T)AG(C/A/T)ACC(A/G)
CGGA(C/G)AG(T/C/A)(G/A)CC], and this may determine the relative
neuron-speciﬁcity of neuronatin.
When studied in porcine placenta, the neuronatin-promoter is noted
to contain an E-box binding site (CANNTG) that when activated allows
neuronatin to regulate glucose transportation and promote placental
growth [10]. The promoter also has a speciﬁc binding site for Beta2/
NeuroD1, a transcriptional factor that plays an important role in the de-
velopment of the pancreas and the nervous system. A carbohydrate re-
sponse element (ChRE) is also present within the promoter [11].
Neuronatin is a paternally-expressed imprinted gene with an imprint
control region embedded within the ﬁrst intron of the gene [12]. Im-
printing is also regulated using three CpG islands located in the
neuronatin promoter. These imprint control regions have the potential
to regulate gene expression by cytosine methylation. In the event that
these imprint control regions lose their methylation, aberrant cell
growth is triggered, particularly manifested in embryonic neoplasms
[13].
4. NeuronatinmRNA: primarily neuronal expression
Neuronatin mRNA is mainly expressed in the brain during
neurogenesis. In the rat, the alpha-form appears in the ﬁrst week of em-
bryogenesis and the beta-form in the second week coinciding with the
closure of the neural tube and the onset of neuroepithelial proliferation
and neuroblast generation. The expression of both isoforms declines by
the end of the second postnatal week. However, traces of neuronatin
mRNA continued to be present even in the adult brain including the hy-
pothalamus and pituitary [3,14]. The cellular function of neuronatin
mRNA was investigated in PC12 cells, an established neuronal cell line.
Neuronatin mRNA is abundant in undifferentiated PC12 cells but
downregulates when the cells are allowed to differentiate with nerved contains three exons and two introns. The promoter contains modiﬁed TATA (−27) and
rt site is located 124 based upstream from the methionine (ATG) initiation codon and 27
RSE)which governs neuron-speciﬁc expression is observed at−421. Regulatory elements
tin gene (GenBank Accession #U31767; Adapted from Joseph R. PhD Thesis, University of
185R.M. Joseph / Genomics 103 (2014) 183–188growth factor supporting a role in neuronal growth [15,16]. Neuronatin
has been shown to transform embryonic stem cells from a pluripotent
state into a neural fatemediated by the release of calcium from intracel-
lular stores [17]. Other investigators have noted that the mouse homo-
log of neuronatin is ﬁrst expressed in rhombomeres-3 and 5 of the
developing brainstem implicating this gene in the determination of
hindbrain segmentation and the folding of the primitive neural tube
[18].
The earlier work focused on the abundant expression of neuronatin
in the brain. However, it is now known that the gene is also expressed
in other neural tissues such as the dorsal root ganglion [19,20], supraop-
tic nucleus [21] and peripheral nerve sheath tumors [22]. Outside of the
brain , neuronatin is expressed in several tissues including in the pancre-
as [23–25], anterior pituitary [26–28], thyroid [29], and skin [30]. In the
skin, neuronatin regulates keratinocyte differentiation by up-regulating
involucrin [31].
5. Neuronatin protein: energy metabolism and glycogen synthesis
The neuronatin protein has two distinct domains, a hydrophobic N-
terminal arranged as a transmembrane alpha-helix and a hydrophilic
C-terminal. It is a member of a class of proteins referred to as
proteolipids [4]. Proteolipids are typically small regulatory subunits of
membrane channels in the endoplasmic reticulumand facilitate calcium
inﬂux allowing for the normal folding and assembly of proteins.
Neuronatin protein promotes glycogen synthesis and the regulation of
energy metabolism by activating intracellular signaling. In fact,
neuronatin is known to increase calcium levels in embryonic stem
cells [17].Fig. 2.Neuronatin cDNA isoforms.Neuronatin-alphahas three exons: Exon-1 has 72 nucleotides
Exon-3 has 90 nucleotides encoding 30 residues.Neuronatin-beta is identical to Neuronatin-alph
for neuronatin-alpha and #U09785 for neuronatin-beta; Adapted from Joseph R. PhD Thesis, UnNeuronatin also stimulates the release of calcium ions in the den-
drites of hippocampal neurons necessary to process in-situ translation
[32]. The translation of neuronatin in dendrites provides a means for
rapidly eliciting in situ change in dendritic protein levels necessary for
synaptic plasticity. It also induces glycogen synthesis through de-
phosphorylation and activation of glycogen synthase. This is facilitated
by neuronatin activating P13-kinase and causing GSK-3b phosphoryla-
tion [33]. In porcine placenta the neuronatin-promoter has been
shown to contain an E-box binding site that when activated allows
neuronatin to regulate glucose transportation and augment placental
growth [10].6. Misfolded neuronatin protein: aggregates in Lafora disease
Lafora disease is an autosomal recessive neurodegenerative disease
manifesting with intractable myoclonic epilepsy, dementia and death
within a decade.Neuronatin is a substrate formalin, an E3-Ubiquitin ligase
[33]. Ubiquitin–proteasome system is responsible for the degradation of
misfolded proteins that may accumulate in cells when the endoplasmic
reticulum is stressed. Aggregosomes are formed by the accumulation
and deposition ofmisfolded proteinwhich is amajor threat to the normal
functioning of the endoplasmic reticulum. Such perturbations to the en-
doplasmic reticulum may hasten cell damage by apoptosis. Malin works
alongside another enzyme called laforin and together function to regulate
proteasomal degradation of proteins including glycogen synthase and
glycogen debranching enzyme, both essential for the synthesis of glyco-
gen. Malin enhances the clearance of intracellular misfolded proteins
and protects the cell from self-destruction.encoding 24 amino acid residues; Exon-2 has 81 nucleotides encoding 27 amino acids; and
a except that themiddle exon (exon-2) is spliced out (box) (GenBank Accession #U08290
iversity of London 1996, page 124-125 ).
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protein and enhances its degradation through the proteasome [34]. The
experimental inhibition of proteasome function is known to cause the
accumulation of neuronatin protein aggregates within cells. And muta-
tion in the malin gene causes neuronatin protein to misfold and disrupt
the endoplasmic reticulum. In fact, misfolded neuronatin aggregates ac-
cumulate as cytotoxic intracellular deposits (Lafora bodies) in patients
with Lafora disease. Lafora bodies are also present in tissues other than
neurons including skin, liver and heart muscle. Skin specimens exhibit
abnormally high levels of neuronatin protein in patients with Lafora dis-
ease, potentially a simpler diagnostic option. The neuronatin-aggregates
also occur within cortical neurons, especially within parvalbumin-
positive GABAergic interneurons in the cortex, hippocampus, amygdala,
and hypothalamus. Excessive loss of these inhibitory interneurons may
account for the dominance of seizures in victims of Lafora disease. A
similar reasoning may be extended to phenylketonuria where high
levels of neuronatin have also been observed [35].
7. Neuronatin and diabetes: destruction of islet beta cells
Neuronatin is normally expressed in pancreatic islet beta cells
[23–25]. However, abnormal expression of neuronatin especially its
beta-isoform causes the destruction of pancreatic islet beta cells [11,36].
The promoter of the neuronatin gene has a speciﬁc binding site for
Beta2/NeuroD1, a transcriptional factor that plays an important role in
the development of the pancreas and neural tissue. There is also a carbo-
hydrate response element (ChRE) within the promoter of the neuronatin
gene that might regulate its expression under high glucose conditions.
The pancreatic beta cells are highly susceptible to endoplasmic
reticulum-mediated apoptosis. Under chronic high glucose conditions
that simulate uncontrolled diabetes, the ratio of neuronatin-beta to
neuronatin-alpha increases. The increased amounts of neuronatin-beta
protein accumulate as misfolded ubiquitin-positive aggregate structures
that leads to the destruction of islet beta cells and thereby diabetes
mellitus. Neuronatin activates nuclear factor-kB (NF-kB)-regulated
genes including inﬂammatory cytokines, chemokines and cell adhesion
molecules in aortic endothelium of mice with obesity and diabetes [37].
Silencing of neuronatin expression reduces both basal and insulin-
stimulated glucose uptake and glycogen synthesis likely mediated by a
reduction of GLUT1 protein [38].
Neuronatinmay also play an indirect role in diabetes through its ef-
fects on glycogen and lipid metabolism [39]. Neuronatin is abundantly
expressed in adipose tissue; however, the level is lower in obese sub-
jects. Hypothalamic neuronatin-beta levels are decreased following gas-
tric bypass surgery [40]. Neuronatin enhances CREB phosphorylation
through increasing free intracellular calcium [41]. Single nucleotide
polymorphisms in the neuronatin gene are also associated with severe
obesity in humans [42].
8. Neuronatin is an imprinted gene: paternally-expressed and
maternally-silenced
Genomic imprinting is a form of transcriptional regulation in which
genes are subject to epigenetic modiﬁcations such as DNA methylation
and histone modulation based on the gender of the parent of origin
[43,44]. Human neuronatin is located on chromosome-20q11.2-12 and
the mouse equivalent in the distal portion of chomosome-2, both
these imprint regions reside outside ofmore established imprinted clus-
ters [5,6]. Neuronatin is only expressed from the paternally derived al-
lele while the maternal allele is silenced by methylation [45,46].
During embryogenesis the onset of gender-speciﬁc gonadal hormone
changes may trigger imprinting [47]. Interestingly, Neuronatin gene is
actually located within the ﬁrst intron of a larger tumor suppressor
gene called BLCAP (Bladder Cancer Associated Protein) [7,8]. BLCAP is
not an imprinted gene except within the brain. Other investigatorshave also identiﬁed an imprint control region for neuronatin that is em-
bedded within the ﬁrst intron of the neuronatin gene [12].
Neuronatin is the ﬁrst identiﬁed eutherian-speciﬁc imprinted gene
[48]. In mammalian cells the only known epigenetic modiﬁcation to di-
rectly affect DNA is cytosine-methylation at cytosine-phosphate-
guanine (CpG) dinucleotide sites. Inappropriate methylation of CpG
islands within the promoter is associated with silencing of relevant
genes [49]. The level of methylation can be modiﬁed by changes in the
environment and by altering the intake of methyl donors in the diet
[50,51]. A high level of methylation of these islands is suspected to pre-
vent access to regulatory elements in the gene. During the highly con-
trolled process of normal development and after the embryonic
growth has subsided, genomic imprinting helps to silence transcription.
However, loss or change in the level of methylation of imprinted genes
may allow these same developmental genes to trigger and propagate
uncontrolled cancerous growth.
9.Neuronatin and cancer: thematernal allele loses DNAmethylation
There are three CpG islands located in the promoter region of
neuronatin gene that have the potential to regulate gene expression by
cytosinemethylation [13]. Should this imprint control region losemeth-
ylation, aberrant cell growth is triggered especially in embryonic neo-
plasms such as Wilm's tumor [52]. The more aggressive variants of
human glioblastoma multiforme contain areas of stem cell lineage that
express neuronatin and these patients carry a worse prognosis [53].
Loss of methylation and consequent changes in the expression of
neuronatin alter the growth phase of medulloblastoma [54,55], neuro-
blastoma [56,57] andmyxoid liposarcoma [58].Neuronatin is also highly
expressed in large cell lung cancer [59,60]. The expression of neuronatin
gene in adenocarcinoma is associated with a worse prognosis [61,62].
On the other hand and somewhat unexpectedly hypermethylation of
the neuronatin locus has been associated with pediatric leukemia [63].
The metastatic cascade comprises of a series of steps that allows for
invasion, migration, dissemination and colonization of target organs.
The present understanding of the process by which cancers spread and
metastasize is limited [64–66]. Micro RNAs (miRNA) are small noncod-
ing RNAs (18–23nucleotides) that regulate gene expression by sequence
speciﬁc binding to mRNA and thereby repressing the translation of new
mRNA or accelerating the degradation of existing mRNA [67]. Among a
number of miRNAs obtained from cancer tissue, miRNA-708 selectively
targets neuronatin to decrease intracellular calcium resulting in de-
creased cell migration and impaired metastasis, a ﬁnding that may
have therapeutic application.
Neuronatin is one of the most abundant transcripts present in the
normal adult anterior pituitary gland. It is expressed in all of the differ-
ent hormonal secreting cell types [26–28]. The majority of pituitary ad-
enomas remain benign, however, one third will show invasive
characteristics and some will become metastatic [68]. As would be ex-
pected methylation-mediated neuronatin silencing is a frequent ﬁnding
in pituitary adenomas that have no malignant characteristics [69].
10. Conclusion: are misfolded-NNAT aggregates a ubiquitous partic-
ipant in neuronal loss?
Neuronatin is a unique gene thatwas initially identiﬁed in the devel-
oping brain. The gene retains a high degree of homology across mam-
malian species. The mRNA has two isoforms, alpha and beta, and the
protein functions as a membrane-bound proteolipid. Neuronatin pro-
tein is a substrate for malin, an E3-ubiquintin ligase. Under normal
conditions, malin helps to degrade neuronatin protein through the
cellular endoplasmic reticulum machinery. It has been shown that
mutations in the malin gene result in the misfolding and accumulation
of neuronatin protein as intracellular deposits which is a characteristic
feature of Lafora disease, a progressive and fatal neurodegenerative dis-
ease. For reasons that are not fully understood neurons are excessively
187R.M. Joseph / Genomics 103 (2014) 183–188susceptible to the noxious effect of misfolded neuronatin-aggregates.
Under high glucose conditions simulating diabetes, the expression of
neuronatin-beta protein increases, misfolds, aggregates and destroys
pancreatic islet cells.
Neuronatin is imprinted and expressed only from the paternal
allele. A decrease or loss of methylation of the maternal allele leads
to aberrant expression of neuronatin and thereby enhanced growth
and spread of glioblastoma multiforme. Neuronatin is also translated
in-situ within dendrites and is observed within paralbumin-positive
GABAergic neurons raising the possibility of a role in learning and
synaptic plasticity.
The current understanding of the function of neuronatin including its
potential to misfold and form cytotoxic aggregates raises the possibility
that this gene may function as part of a common downstream mecha-
nism propagating aberrant neuronal growth and destruction. A better
understanding of these mechanisms could provide therapeutic targets
to help slow the inexorable neuronal loss accompanying devastating
neurodegenerative diseases.Acknowledgments
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